|
|
Article: Callisto Names Veteran Investment Banker and Biotech Specialist Dan D'Agostino to Key Technology and Business Growth Role; D'Agostino to Direct M&A and Efforts to Expand Callisto Pipeline of New Drug Technologies and Candidates.
- Article from:
- Business Wire
- Article date:
- October 14, 2005
CopyrightCOPYRIGHT 2005 Business Wire. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
NEW YORK -- Callisto Pharmaceuticals, Inc. (AMEX:KAL) (FWB:CA4), a developer of new drug treatments in the fight against hematological cancers and related diseases, has named Dan D'Agostino, a veteran investment banker with extensive background in the healthcare and biotech sectors, to the position of Chief Business Officer, in which he will spearhead the Company's M&A and corporate development activities to expand its technology and product portfolio.
Mr. D'Agostino brings Callisto approximately 15 years' experience in investment banking at some of the industry's most prominent institutions, most recently as co-head of healthcare investment banking at Punk, ...